ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for the MULTIDISCIPLINARY CANCER CARE TEAM and the PATIENTS they serve since 1997
Meetings & Education
ASCO Direct™ Highlights - South Carolina
Financial Advocacy & Patient Assistance
SCOS Fellows Travel Award
Patient Advocacy Organizations
State & Federal Resources
Off-Label Use Literature
Find A Clinical Trial
National Professional Organizations
SCOS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Nivolumab Plus Ipilimumab for Metastatic Colorectal Cancer
On July 11, the Food and Drug Administration (FDA) approved nivolumab (Opdivo, Bristol-Myers Squibb) plus Yervoy (ipilimumab, Bristol-Myers Squibb) for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Read the full Bristol-Myers Squibb press release here.
Tweets by OSSatACCC